175 related articles for article (PubMed ID: 38236456)
1. Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis.
Xie H; Zhang Y; Zhu Z; Wei J; Ainiwaer G; Ge W
Rheumatol Ther; 2024 Apr; 11(2):269-283. PubMed ID: 38236456
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.
Zuo CZ; Gong Y; Hou XY; Zhang YF; Peng WX; Zhu RH; Zhong DF; Chen XY
Clin Ther; 2018 Aug; 40(8):1347-1356. PubMed ID: 30017171
[TBL] [Abstract][Full Text] [Related]
3. Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects.
Yang L; Shen Q; Hu C; Wang Y; Zhu X; Shu S; Luo Z
Drug Des Devel Ther; 2022; 16():3865-3876. PubMed ID: 36388081
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of imrecoxib in patients with renal insufficiency.
Pei Q; Xie JL; Huang J; Liu WY; Yang XY; Wang Y; Li W; Tan HY; Zhang H; Yang GP
Eur J Clin Pharmacol; 2019 Oct; 75(10):1355-1360. PubMed ID: 31243478
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis.
Sun X; Zhen X; Hu X; Li Y; Gu S; Gu Y; Zhao Z; Yang W; Dong H
Ann Transl Med; 2021 Apr; 9(7):575. PubMed ID: 33987273
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.
Gao GM; Li YM; Zheng XL; Jiang DB; Zhang LL; Xu PH; Liu SY; Zheng ZH; Kan QC
Med Sci Monit; 2017 Jun; 23():2985-2992. PubMed ID: 28626213
[TBL] [Abstract][Full Text] [Related]
7. A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
Zong HX; Xu SQ; Wang JX; Chu YR; Chen KM; Wang C; Tong WQ; Wang XL
Drug Des Devel Ther; 2022; 16():2755-2765. PubMed ID: 36033132
[TBL] [Abstract][Full Text] [Related]
8. Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.
Zhang K; Miao X; Jiang L; Cui S; Liu Z; Wang Z
Inflammopharmacology; 2023 Aug; 31(4):1813-1822. PubMed ID: 37306938
[TBL] [Abstract][Full Text] [Related]
9. Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial.
Jiang Y; Qi L; Liu J; Wu H; Li Y; Zou L; Guo Z; Wang J; Li H
Ann Transl Med; 2021 Mar; 9(6):469. PubMed ID: 33850866
[TBL] [Abstract][Full Text] [Related]
10. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
[TBL] [Abstract][Full Text] [Related]
11. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.
Chen XH; Bai JY; Shen F; Bai AP; Guo ZR; Cheng GF
Acta Pharmacol Sin; 2004 Jul; 25(7):927-31. PubMed ID: 15210067
[TBL] [Abstract][Full Text] [Related]
12. Proteomics Analysis of Knee Subchondral Bone Identifies Differentially Expressed Proteins Associated with Osteoarthritis.
Tan Q; Li F; Zhang K; Liu Z; Tian Y; Zhu T
J Proteome Res; 2024 Feb; 23(2):738-748. PubMed ID: 38206579
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of preemptive analgesia with imrecoxib on analgesia after anterior cruciate ligament reconstruction: a randomized controlled study].
Sun Y; Lin Y; Li Q; Li B; Wang D; Huang X
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2023 Aug; 37(8):982-988. PubMed ID: 37586799
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis.
Sun X; Zhen X; Hu X; Li Y; Gu S; Gu Y; Zhao Z; Yang W; Dong H
Cost Eff Resour Alloc; 2021 Apr; 19(1):22. PubMed ID: 33879168
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometry-based proteomics identify novel serum osteoarthritis biomarkers.
Tardif G; Paré F; Gotti C; Roux-Dalvai F; Droit A; Zhai G; Sun G; Fahmi H; Pelletier JP; Martel-Pelletier J
Arthritis Res Ther; 2022 May; 24(1):120. PubMed ID: 35606786
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry.
Hou X; Dai X; Yang Y; Zhang Y; Zhong D; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Aug; 1122-1123():58-63. PubMed ID: 31153132
[TBL] [Abstract][Full Text] [Related]
17. Dose investigation of imrecoxib in patients with renal insufficiency based on modelling and simulation.
Li Y; Wang J; Huang J; Yu J; Wang Y; Tan H; Zhang H; Yang G; Pei Q
Eur J Pharm Sci; 2020 Sep; 152():105449. PubMed ID: 32621967
[TBL] [Abstract][Full Text] [Related]
18. Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study.
Guo W; Liu Y; Li J
Inflammopharmacology; 2022 Jun; 30(3):875-881. PubMed ID: 35445990
[TBL] [Abstract][Full Text] [Related]
19. Resistin as a potential diagnostic biomarker for sepsis: insights from DIA and ELISA analyses.
Lan Y; Guo W; Chen W; Chen M; Li S
Clin Proteomics; 2024 Jul; 21(1):46. PubMed ID: 38951753
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial.
Xie Y; Tu L; Zhang Y; Yu Q; Wu H; Ye S; Li H; Chen Z; Wu J; Cao S; Wei Q; Gu J
J Ethnopharmacol; 2022 Mar; 285():114731. PubMed ID: 34634368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
